JP2024506229A5 - - Google Patents
Info
- Publication number
- JP2024506229A5 JP2024506229A5 JP2023525964A JP2023525964A JP2024506229A5 JP 2024506229 A5 JP2024506229 A5 JP 2024506229A5 JP 2023525964 A JP2023525964 A JP 2023525964A JP 2023525964 A JP2023525964 A JP 2023525964A JP 2024506229 A5 JP2024506229 A5 JP 2024506229A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- levocloperastine
- pharmaceutically acceptable
- acceptable salt
- dizziness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021047025 | 2020-10-28 | ||
| IN202021047025 | 2020-10-28 | ||
| PCT/IN2021/050886 WO2022091118A1 (en) | 2020-10-28 | 2021-09-10 | Anti-vertigo compound and pharmaceutical compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506229A JP2024506229A (ja) | 2024-02-13 |
| JP2024506229A5 true JP2024506229A5 (https=) | 2024-09-19 |
| JP7837967B2 JP7837967B2 (ja) | 2026-03-31 |
Family
ID=81382136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525964A Active JP7837967B2 (ja) | 2020-10-28 | 2021-09-10 | 抗眩暈組成物及びその医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230390271A1 (https=) |
| EP (1) | EP4236923A4 (https=) |
| JP (1) | JP7837967B2 (https=) |
| CN (1) | CN116963737A (https=) |
| AU (1) | AU2021368635A1 (https=) |
| CA (1) | CA3200533A1 (https=) |
| WO (1) | WO2022091118A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4299059A1 (en) | 2022-07-01 | 2024-01-03 | Labelic Analysis, S.L. | Composition for the treatment of tinnitus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228561B (it) * | 1989-03-03 | 1991-06-21 | Magis Farmaceutici | Isomero otticamente attivo della cloperastina avente attivita' antitussiva, processo per la sua preparazione e composizioni farmaceutiche che lo contengono. |
| EP0894794A1 (en) * | 1997-07-31 | 1999-02-03 | AESCULAPIUS FARMACEUTICI S.r.l. | Optical isomers of cloperastine |
| JP2004269513A (ja) | 2003-02-19 | 2004-09-30 | Rohto Pharmaceut Co Ltd | 固形製剤 |
| US20090176792A1 (en) * | 2008-01-07 | 2009-07-09 | Auspex Pharmaceuticals, Inc. | Substituted dibenzhydrylpiperazines |
| WO2019004953A1 (en) * | 2017-06-29 | 2019-01-03 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY |
-
2021
- 2021-09-10 CA CA3200533A patent/CA3200533A1/en active Pending
- 2021-09-10 US US18/033,993 patent/US20230390271A1/en active Pending
- 2021-09-10 WO PCT/IN2021/050886 patent/WO2022091118A1/en not_active Ceased
- 2021-09-10 CN CN202180074091.1A patent/CN116963737A/zh active Pending
- 2021-09-10 EP EP21885539.3A patent/EP4236923A4/en active Pending
- 2021-09-10 JP JP2023525964A patent/JP7837967B2/ja active Active
- 2021-09-10 AU AU2021368635A patent/AU2021368635A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019306787B2 (en) | Extended release formulations of cannabinoids | |
| JP7378781B2 (ja) | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 | |
| US10071083B2 (en) | Use of gaboxadol in the treatment of tinnitus | |
| ES3009607T3 (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| US20230285408A1 (en) | Method of treating dementia | |
| CA2667924A1 (en) | The use of pramipexole or a salt thereof for the treatment of parkinson's disease | |
| JP2019513814A (ja) | 改善される運動性及び認知機能のためのアセチル−ロイシン又はその薬学的に許容される塩 | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2015523986A5 (https=) | ||
| JP2024506229A5 (https=) | ||
| TW201841635A (zh) | 用於治療抑鬱症之組合物及方法 | |
| US11744833B2 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
| EP4478887A1 (en) | Novel pharmaceutical compositions and methods for treatment of insomnia | |
| TW201141468A (en) | Neramexane for the treatment or prevention of inner ear disorders | |
| JP2014502981A (ja) | ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン | |
| JP7837967B2 (ja) | 抗眩暈組成物及びその医薬組成物 | |
| JP2013173759A (ja) | 平衡障害の治療用薬剤の製造のためのアセチル−ロイシンの使用 | |
| CN111093772A (zh) | 偏头痛的治疗 | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| CN121129884A (zh) | 维生素b复合物在制备治疗抗眩晕药物中的应用 | |
| Roller et al. | Dizziness and vertigo | |
| TWI642431B (zh) | Ｎ－乙醯半胱胺酸用於治療突發性感覺神經性聽力損失的方法 | |
| Kiran et al. | AN OPEN-LABELED, MULTICENTRIC, POST-MARKETING SURVEILLANCE (PMS) TO SUBSTANTIATE THE SAFETY AND EFFICACY OF SINAREST SYRUP IN PATIENTS OF COMMON COLD. | |
| JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| RU2023128802A (ru) | Фармацевтическая композиция, содержащая селективный ингибитор jak3/jak1/tbk1, и ее медицинское применение |